semaglutide fda news warns about compounded versions of semaglutide, used for diabetes, weight loss Semaglutide FDA Approval vs Compounded

Key Takeaways: Originally developed for diabetes management, Rybelsus and Jardiance have demonstrated promising potential in facilitating weight loss in type 2 diabetes patients

however, its therapeutic effects eventually wear off and can even cause motor complications, such as fluctuations and dyskinesias

Certain detrimental effects on a childs health are strongly correlated with maternal obesity and gestational diabetes underscoring the need for a safer and more efficient drug (89)

Minimal responders lost less than 5%

The evidence is mixed and depends strongly on the reason for use

The incidence of 3-point MACE was ascertained from the SUSTAIN-6 prospectively collected, adjudicated event dataset